<DOC>
	<DOC>NCT01955980</DOC>
	<brief_summary>The study should create data for the selection of a clinically relevant endpoint to assess the potential of Buparid/PARI SINUS to postpone sinus surgery in patients with chronic Rhinosinusitis.</brief_summary>
	<brief_title>Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis</brief_title>
	<detailed_description />
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Patient with confirmed diagnosis of chronic rhinosinusitis Patient without alternative other than sinus surgery Patient's written informed consent obtained prior to any screening or studyspecific procedure Male or female, ≥ 18 years of age Patient is able to undergo nasal therapy without restrictions Capable to correctly use the PARI SINUS device Capable of understanding the purpose and risk of the clinical trial Female patients with childbearing potential must have a negative urine pregnancy test prior to first IMP administration. Patient is able to participate in the study according to Investigator's opinion Patients with cystic fibrosis Patients with polyposis nasi grade IIV Patients with prior FESS (Functional Endoscopic Sinus Surgery) Pregnant or breastfeeding women Any active invasive bacterial, viral or fungal infection within one week prior to first investigational medicinal product (IMP) administration No clinically relevant abnormal parameters of vital signs, blood biochemistry or renal/hepatic function Unlikely to comply with visits, inhalation procedures or other measurements scheduled in the protocol Receipt of an investigational drug as part of a clinical trial within 4 weeks prior to first administration of IMP Any coexisting medical condition that in the Investigator's judgement will substantially increase the risk associated with the patient's participation in the clinical trial Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary procedures Drug or alcohol abuse Endstage malignancies Known hypersensitivity to Budesonide Patients with oral steroid therapy within the last 3 months Patients needing &gt; 1 mg/day Budesonide (or steroidal equivalent) for therapy of asthma Patients on therapy with leukotrienereceptor antagonists, decongestants, antihistamines or antibiotics Patients with frequent epistaxis (&gt; 1 episode per week)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>CRS</keyword>
	<keyword>without polyposis</keyword>
</DOC>